The treatment of infections caused by multidrug-resistant Gram-negative bacteria has become increasingly complex, particularly when organisms produce metallo-beta-lactamases (MBLs) such as New Delhi metallo-beta-lactamase (NDM). Two therapeutic strategies that have received attention in this setting are aztreonam-avibactam and the combination of ceftazidime-avibactam plus aztreonam. Although both approaches involve aztreonam and an avibactam-containing regimen, they are...Read More